Search

Your search keyword '"Poly(ADP-ribose) Polymerases genetics"' showing total 2,135 results

Search Constraints

Start Over You searched for: Descriptor "Poly(ADP-ribose) Polymerases genetics" Remove constraint Descriptor: "Poly(ADP-ribose) Polymerases genetics"
2,135 results on '"Poly(ADP-ribose) Polymerases genetics"'

Search Results

1. IRF1-mediated upregulation of PARP12 promotes cartilage degradation by inhibiting PINK1/Parkin dependent mitophagy through ISG15 attenuating ubiquitylation and SUMOylation of MFN1/2.

2. Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.

3. Dispensability of HPF1 for cellular removal of DNA single-strand breaks.

4. Identification of porcine PARP11 as a restricted factor for pseudorabies virus.

5. Redundant but essential functions of PARP1 and PARP2 in DNA ligase I-independent DNA replication.

6. PARP9 affects myocardial function through TGF-β/Smad axis and pirfenidone.

7. Adaptive genetic mechanisms in mammalian Parp1 locus.

8. Regulation of PARP1/2 and the tankyrases: emerging parallels.

9. Deltex family E3 ligases specifically ubiquitinate the terminal ADP-ribose of poly(ADP-ribosyl)ation.

10. A multidomain PARP14 construct suitable for bacterial expression.

11. Apurinic/apyrimidinic endonuclease 1 has major impact in prevention of suicidal covalent DNA-protein crosslink with apurinic/apyrimidinic site in cellular extracts.

12. Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts.

13. PARP10 promotes the repair of nascent strand DNA gaps through RAD18 mediated translesion synthesis.

14. Body-wide genetic deficiency of poly(ADP-ribose) polymerase 14 sensitizes mice to colitis.

15. PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks.

16. PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer.

17. PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation.

18. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.

19. PARP-2 mediates cardiomyocyte aging and damage induced by doxorubicin through SIRT1 Inhibition.

20. Achillea fragrantissima (Forssk.) Sch.Bip instigates the ROS/FADD/c-PARP expression that triggers apoptosis in breast cancer cell (MCF-7).

21. A PARP1-TIMELESS alliance in cancer therapy.

22. Specific and shared biological functions of PARP2 - is PARP2 really a lil' brother of PARP1?

23. PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response.

24. A Novel Inhibitor of Poly( ADP - R ibose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA D amage- A ctivated cGAS-STING Pathway.

25. Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.

26. Network integration of thermal proteome profiling with multi-omics data decodes PARP inhibition.

27. PARP14 correlates with GBM proliferation and poor prognosis by elevating expression of SAMD/SAMD9L.

28. Cooperative nucleic acid binding by Poly ADP-ribose polymerase 1.

29. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.

30. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.

31. ART1 knockdown decreases the IL-6-induced proliferation of colorectal cancer cells.

32. Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1.

33. High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.

34. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.

35. Targeting BRCA and PALB2 in Pancreatic Cancer.

36. Crystal structure and biochemical activity of the macrodomain from rubella virus p150.

37. Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.

38. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.

39. PARP inhibitors for prostate cancer.

40. PARP Inhibitors in Breast Cancer: a Short Communication.

41. Poly(ADP-ribose) polymerase-1 affects vasopressin-mediated AQP2 expression in collecting duct cells of the kidney.

42. GATA binding protein 6 regulates apoptosis in silkworms through interaction with poly (ADP-ribose) polymerase.

43. Loss of Adaptive DNA Breaks in Alzheimer's Disease Brains.

44. Immunomodulatory roles of PARPs: Shaping the tumor microenvironment, one ADP-ribose at a time.

45. Cas9 is mostly orthogonal to human systems of DNA break sensing and repair.

46. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.

47. FUS RRM regulates poly(ADP-ribose) levels after transcriptional arrest and PARP-1 activation on DNA damage.

48. Transcriptome screening identifies TIPARP as an antiviral host factor against the Getah virus.

49. Exploration of glycosyltransferases mutation status in cervical cancer reveals PARP14 as a potential prognostic marker.

50. PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell- and tissue-specific manner.

Catalog

Books, media, physical & digital resources